Delving into the Latest Updates on Allogeneic Bone Marrow Derived Mesenchymal Stem Cells(Nanjing Medical University) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms-

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

Lupus Nephritis

Originator Organization

Nanjing Medical University

Active Organization-

Inactive Organization

Nanjing Medical University

License Organization-

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

This study will explore a new approach to treat patients with a medical condition known as systemic lupus erythematosus (SLE) who have been resistant to previous treatments using a new population of cells with capability to restore a normal immune system that will no longer attack the body.
The stated hypothesis is that the SLE condition is caused by an abnormal immune system that can be restored by replenishing the body with a new population of progenitor cells.

Start Date01 Mar 2007

Sponsor / Collaborator

Nanjing Medical University

[+1]

100 Clinical Results associated with Allogeneic Bone Marrow Derived Mesenchymal Stem Cells(Nanjing Medical University)

Login to view more data

100 Translational Medicine associated with Allogeneic Bone Marrow Derived Mesenchymal Stem Cells(Nanjing Medical University)

Login to view more data

100 Patents (Medical) associated with Allogeneic Bone Marrow Derived Mesenchymal Stem Cells(Nanjing Medical University)

Login to view more data

100 Deals associated with Allogeneic Bone Marrow Derived Mesenchymal Stem Cells(Nanjing Medical University)

Login to view more data